Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Phase III OCEAN trial: melflufen non-inferior to pomalidomide for relapsed refractory multiple myeloma

Written by Louis Gautier, Future Science Group

multiple myeloma

Oncopeptides AB (Stockholm, Sweden) recently announced positive results from their head-to-head Phase III OCEAN trial, comparing melflufen plus dexamethasone with pomalidomide plus dexamethasone in relapsed multiple myeloma patients who are refractory to both lenalidomide and their last treatment. The trial’s primary endpoint was to compare progression-free survival (PFS) between the two treatment arms, with the aim of offering additional viable treatment options for the growing population of relapsed multiple myeloma patients who are refractory to front-line treatments. The trial’s protocol was published open access in March 2020 in Future Oncology along with an infographic. [1] Read the full Future Oncology...

To view this content, please register now for access

It's completely free